Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.61 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.61 |
| ▸ | F2 | P00734 | 4/20 | 0.60 |
| ▸ | NPY1R | P25929 | 4/20 | 0.57 |
| ▸ | NPY2R | P49146 | 4/20 | 0.57 |
| ▸ | NPY4R | P50391 | 4/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.57 |
| ▸ | TFPI | P10646 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4139781 | 1.00 | NMUR2 (0.61) | NMUR2NMUR1F2NPY1RNPY2R | |
| Trifluoroacetic Acid SCHEMBL29454826 | 1.00 | NMUR2 (0.61) | NMUR2NMUR1F2NPY1RNPY2R | |
| Trifluoroacetic Acid SCHEMBL16029740 | 1.00 | NMUR2 (0.61) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL23278082 | 0.98 | NMUR2 (0.64) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL29389211 | 0.98 | NMUR2 (0.64) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL25739 | 0.98 | NMUR2 (0.64) | NMUR2NMUR1F2NPY1RNPY2R | |
| Acetic Acid SCHEMBL2037978 | 0.97 | NMUR2 (0.63) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL28366588 | 0.97 | NMUR2 (0.65) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL30753221 | 0.96 | NMUR2 (0.61) | NMUR2NMUR1F2NPY1RNPY2R | |
| SCHEMBL23630197 | 0.96 | NMUR2 (0.62) | NMUR2NMUR1F2NPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918622-B2 | Ready-to-use bivalirudin compositions | MAIA Pharmaceuticals, Inc. (US) | 2024-03-05 | — | — | US | claimed |
| US-20230293626-A1 | READY-TO-USE BIVALIRUDIN COMPOSITIONS | MAIA Pharmaceuticals, Inc. | 2023-09-21 | — | — | US | claimed |
| US-20230210938-A1 | READY-TO-USE BIVALIRUDIN COMPOSITIONS | MAIA Pharmaceuticals, Inc. | 2023-07-06 | — | — | US | claimed |
| CN-116375848-A | Preparation and purification method of polypeptide raw material medicine bivalirudin | 苏州宇莘新材料有限公司 | 2023-07-04 | — | — | CN | claimed |
| CN-111450242-A | Bivalirudin injection preparation and preparation method and application thereof | 上海上药第一生化药业有限公司 | 2020-07-28 | — | — | CN | claimed |
| WO-2011071799-A2 | PURIFICATION OF BIVALIRUDIN | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-06-16 | — | — | WO | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250375388-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | UNIV MICHIGAN REGENTS (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250295587-A1 | COMPLEX LIPID NANOPARTICLES ENCAPSULATING POLYPEPTIDES AND USES THEREOF | SAIL BIOMEDICINES, INC. | 2025-09-25 | — | — | US | disclosed |
| EP-4597115-A2 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK | Takeda Pharmaceutical Company Limited (JP) | 2025-08-06 | — | — | EP | disclosed |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-07-03 | — | — | US | disclosed |
| EP-4574040-A2 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | Takeda Pharmaceutical Company Limited (JP) | 2025-06-25 | — | — | EP | disclosed |
| US-20140187745-A1 | METHOD FOR PREPARING BIVALIRUDIN | Chengdu Shengnuo Tech Co., Ltd. (CN) | 2014-07-03 | — | — | US | disclosed |
| CN-102532274-B | Method for preparing bivalirudin | CHENGDU SHENGNUO BIOLOG PHARMACEUTICAL CO LTD | 2014-04-23 | — | — | CN | disclosed |
| CN-103319570-A | Preparation method of bivalirudin | SHENZHEN HYBIO PHARMACEUTICAL | 2013-09-25 | — | — | CN | disclosed |
| CN-102532274-A | Method for preparing bivalirudin | CHENGDU SHENGNUO BIOLOG PHARMACEUTICAL CO LTD | 2012-07-04 | — | — | CN | disclosed |
| US-7985733-B1 | Buffer-based method for preparing bivalirudin drug product | THE MEDICINES COMPANY (US) | 2011-07-26 | — | — | US | disclosed |
| WO-2011071799-A2 | PURIFICATION OF BIVALIRUDIN | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-06-16 | — | — | WO | disclosed |
| US-20090062511-A1 | PROCESS FOR THE PREPARATION OF BIVALIRUDIN AND ITS PHARMACEUTICAL COMPOSITIONS | DR. REDDY'S LABORATORIES, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | NMUR2 2018/4885NMUR1 1851/4885F2 3184/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | NMUR2 3958/4885NMUR1 3649/4885F2 3790/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | NMUR2 2450/4885NMUR1 3714/4885F2 4486/4885 |
| US-20140187745-A1 | METHOD FOR PREPARING BIVALIRUDIN | RNGTT, QPCTL, BCAT2 | NMUR2 944/4885NMUR1 1838/4885F2 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.